Abstract |
Brimonidine is a highly selective α2-adrenergic receptor agonist approved by the FDA for the treatment of rosacea. Rosacea is a major clinical disease with vasodilatation and rash on the centre of the face, and that brimonidine as a vasoconstrictor can act as a remedy for rosacea. However, there is no study of how brimonidine has an effect on rosacea-related immune cells or mechanisms in the skin to improve rosacea. In this study, we observed that clinical features of rosacea induced by LL-37 in Balb/c mice were improved after the application of brimonidine gel, and we also showed a marked decrease in the number of inflammatory cells, especially mast cells (MCs) histologically. Furthermore, we confirmed that mRNA levels of MC enzymes increased by LL-37 were reduced by brimonidine gel. To our knowledge, we first found that brimonidine has a mechanism of treating rosacea by reducing the number and mRNA levels of MC-specific enzymes, an important immune cell in the pathogenesis of rosacea.
|
Authors | Miri Kim, Jongsic Kim, Seo-Won Jeong, Hyunmu Jo, Yu Ri Woo, Hyun Jeong Park |
Journal | Experimental dermatology
(Exp Dermatol)
Vol. 26
Issue 11
Pg. 1143-1145
(11 2017)
ISSN: 1600-0625 [Electronic] Denmark |
PMID | 28500634
(Publication Type: Letter)
|
Copyright | © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Adrenergic alpha-2 Receptor Agonists
- Antimicrobial Cationic Peptides
- Enzymes
- Gels
- RNA, Messenger
- Brimonidine Tartrate
- Cathelicidins
|
Topics |
- Administration, Cutaneous
- Adrenergic alpha-2 Receptor Agonists
(administration & dosage, therapeutic use)
- Animals
- Antimicrobial Cationic Peptides
- Brimonidine Tartrate
(administration & dosage, therapeutic use)
- Cell Movement
(drug effects)
- Disease Models, Animal
- Enzyme Induction
(drug effects)
- Enzymes
(genetics)
- Female
- Gels
- Mast Cells
(enzymology, physiology)
- Mice
- RNA, Messenger
(metabolism)
- Rosacea
(chemically induced, drug therapy, enzymology, pathology)
- Cathelicidins
|